Business Trends– category –
-
Nano-Immunotherapy Targets RCC Microenvironment, Shows Promise Amidst Preclinical Delivery and Manufacturing Hurdles
Dove Medical Press New Zealand Overview Nanotechnology is emerging as a powerful strategy to overcome treatment barriers in renal cell carcinoma (RCC) by enabling nanoparticles (NPs) to remodel the immunosuppressive tumor microenvironmen... -
Serina Therapeutics Non-Exclusively Licenses POZ Polymer Technology for LNP Drug Delivery Formulations to Pfizer, Accelerating Clinical Development of Investigational Drug SER-252
Serina Therapeutics USA Overview Serina Therapeutics has entered a non-exclusive licensing agreement with Pfizer for its proprietary POZ polymer technology for lipid nanoparticle (LNP) drug delivery formulations. This partnership is part... -
Premier Graphene Inc. Announces Strategic Defense Manufacturing Expansion with HGI Industrial Technologies & Nova Graphene Joint Venture to Develop Graphene-Based Ballistic Systems
Mena FN Canada Overview Premier Graphene Inc. announced a strategic expansion into defense manufacturing through a joint venture with its affiliate HGI Industrial Technologies and Nova Graphene. This partnership combines HGI's advanced m... -
Nanoparticles Breach Blood-Brain Barrier for Glioblastoma Treatment, Enabling Magnetic, Photothermal, and Sonodynamic Therapies
Drug Target Review UK Overview Nanomedicine for glioblastoma (GBM) is tackling the formidable challenge of overcoming the blood-brain barrier (BBB) for drug delivery. Nanoparticles not only deliver conventional drugs and nucleic acids to... -
Novel Mesoporous Silica Nanoparticle (MSN)-Based Nanocarrier Targets Non-Small Cell Lung Cancer (NSCLC)
Regeneron ISEF (International Science and Engineering Fair) USA Overview A Regeneron ISEF project unveils a targeted drug delivery nanocarrier for non-small cell lung cancer (NSCLC). This system utilizes doxorubicin hydrochloride (Dox-HC... -
PTC Therapeutics and Eli Lilly to Acquire Sangamo Assets for Up to $264M in Bankruptcy Auction, Bolstering Rare Disease Pipelines
Endpoints News USA Overview PTC Therapeutics and Eli Lilly are set to acquire parts of the bankrupt gene editing biotech Sangamo for up to $264 million following an auction. PTC Therapeutics will acquire Sangamo's Fabry disease candidate... -
Precision and Pace: Liv Hospital Details Step-by-Step Innovations in CAR-T Cell Manufacturing
Liv Hospital Turkey Overview Liv Hospital has released a comprehensive, step-by-step guide to CAR-T cell manufacturing, spanning the entire process from leukapheresis to final formulation. The blueprint emphasizes stringent quality contr... -
China’s Hopstem Biotech Secures Nearly RMB 200 Million in Series C First Close to Advance iPSC Cell Therapy Pipeline Led by hNPC01
Insight, China's Pharmaceutical Industry China Overview China's Hopstem Biotech has completed the first close of nearly RMB 200 million (approximately $27.5 million USD) in Series C funding to advance its iPSC cell therapy pipeline, led ... -
XsellSmart Biopharmaceutical Completes Patient Enrollment in Phase 1 Trial for Universal Cell Therapy XS411 in Parkinson’s-Type Multiple System Atrophy
VCBeat China Overview XsellSmart Biopharmaceutical announced the completion of full participant enrollment in its Phase 1 registrational clinical trial for XS411, a universal cell therapy targeting Parkinson's-type multiple system atroph... -
Intellia Therapeutics Advances CRISPR Gene Therapy Pipeline, Including NTLA-2002 for HAE
Tracxn USA Overview Intellia Therapeutics is a public company advancing therapeutics based on CRISPR/Cas9 technology, with its lead candidate, NTLA-2002, an investigational CRISPR therapy for hereditary angioedema (HAE). The company also...
